Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Fisher Funds Management LTD Boosts Stock Position in Intuitive Surgical ...

📈 Fisher Funds Management LTD raised its ISRG holdings by 28.3% in Q1, adding 31,392 shares to a total position of 142,156 shares valued at $65.5 million.

🏦 Newbridge Financial Services Group Inc. increased its stake by 300% in the fourth quarter, while several other funds initiated new positions totaling over $114,000.

📊 Intuitive Surgical reported Q1 EPS of $2.50, beating analyst estimates of $2.08, and revenue of $2.77 billion, surpassing the consensus of $2.62 billion.

🚀 Revenue grew 23% year-over-year to $2.77 billion, with a net margin of 28.15% and a return on equity of 15.98%.

📉 Citigroup upgraded ISRG to a 'buy' rating with a $590 price target, while other major analysts like Raymond James and HSBC lowered their price targets to the mid-$570s.

👥 Corporate insiders sold approximately $3.06 million in shares recently under pre-arranged Rule 10b5-1 trading plans, reducing their personal holdings.

📉 The stock currently trades at $406.78, which is below its 50-day moving average of $438.43 and 200-day moving average of $489.92.

🏢 Institutional ownership stands at 83.64%, indicating strong interest from large asset managers despite recent insider selling.

🔭 Analysts forecast full-year EPS of $8.57 for the current fiscal year, suggesting continued growth expectations.

🛠️ The company's core business focuses on robotic-assisted surgical systems like the da Vinci platform, which enables minimally invasive procedures.

Bullish Signals
  • Fisher Funds Management LTD significantly increased its position by 28.3% in Q1, adding over $31 million in value to its holdings.
  • Intuitive Surgical beat both EPS and revenue estimates in the last quarter, reporting $2.50 EPS versus a consensus of $2.08.
  • Revenue grew robustly by 23% year-over-year to reach $2.77 billion, demonstrating strong demand for its robotic surgical systems.
  • The company achieved a healthy net margin of 28.15% and a return on equity of 15.98%, indicating efficient operations.
  • Citigroup upgraded the stock to a 'buy' rating with a $590 price target, signaling confidence in future performance.
  • Analysts forecast full-year EPS of $8.57, reflecting expectations for continued profitability and growth.
Risk Factors
  • Several major analysts, including Raymond James, HSBC, BTIG Research, and TD Cowen, recently lowered their price targets to the mid-$570s.
  • Corporate insiders sold approximately $3.06 million in shares recently under pre-arranged Rule 10b5-1 trading plans.
  • The stock is currently trading below its 50-day moving average of $438.43 and 200-day moving average of $489.92.
Full Analysis
Fisher Funds Management LTD significantly increased its position in Intuitive Surgical (ISRG) by 28.3% in the first quarter, acquiring an additional 31,392 shares to hold a total of 142,156 shares valued at approximately $65.5 million. This move makes ISRG the fund's 10th largest holding, representing 1.9% of its portfolio. Several other institutional investors also adjusted their stakes, with Newbridge Financial Services Group Inc. growing its position by 300% in the fourth quarter, while multiple smaller funds initiated new positions ranging from $25,000 to $31,000. Analyst sentiment remains mixed but generally positive regarding Intuitive Surgical's long-term prospects, though recent price targets have been lowered by several major firms. Citigroup upgraded its rating to 'buy' with a $590 target, while Raymond James, HSBC, BTIG Research, and TD Cowen all reduced their price objectives between $574 and $585 in late April. Despite these adjustments, the consensus among 19 buy-side analysts remains a 'Moderate Buy' with an average price target of $573.42. Financially, Intuitive Surgical delivered strong performance in its last quarterly report released on April 21st, beating earnings and revenue estimates. The company reported $2.50 EPS compared to the consensus of $2.08 and generated $2.77 billion in revenue, which exceeded expectations of $2.62 billion. Revenue grew by 23% year-over-year, resulting in a net margin of 28.15% and a return on equity of 15.98%. Analysts forecast full-year EPS of $8.57 for the current fiscal year. Recent insider activity shows executives selling shares under pre-arranged Rule 10b5-1 trading plans, which is standard practice but worth noting alongside institutional accumulation. SVP Iman Jeddi sold over $2.3 million in shares on June 1st, and EVP Gary Loeb sold approximately $170,000 on June 10th, reducing their individual holdings by roughly 46% and 6.5% respectively. The stock currently trades around $406.78, trading below its 50-day moving average of $438.43 but above its 1-year low of $396.68.